ARGX vs. GKOS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ARGX and GKOS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
ARGX trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, GKOS is a standard domestic listing.
| Symbol | ARGX | GKOS |
|---|---|---|
| Company Name | argenx SE | Glaukos Corporation |
| Country | Netherlands | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Equipment & Supplies |
| Market Capitalization | 39.99 billion USD | 5.26 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | May 18, 2017 | June 25, 2015 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of ARGX and GKOS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ARGX | GKOS |
|---|---|---|
| 5-Day Price Return | -5.18% | 4.31% |
| 13-Week Price Return | 15.73% | -3.01% |
| 26-Week Price Return | -12.59% | -40.89% |
| 52-Week Price Return | 15.66% | -24.44% |
| Month-to-Date Return | -7.07% | 6.62% |
| Year-to-Date Return | -7.93% | -38.78% |
| 10-Day Avg. Volume | 0.12M | 1.49M |
| 3-Month Avg. Volume | 0.08M | 1.04M |
| 3-Month Volatility | 36.96% | 36.37% |
| Beta | 0.76 | 0.77 |
Profitability
Return on Equity (TTM)
ARGX
17.59%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
In the upper quartile for the Biotechnology industry, ARGX’s Return on Equity of 17.59% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
GKOS
-12.52%
Health Care Equipment & Supplies Industry
- Max
- 34.53%
- Q3
- 19.38%
- Median
- 9.52%
- Q1
- 4.86%
- Min
- -7.58%
GKOS has a negative Return on Equity of -12.52%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
ARGX
-23.60%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
ARGX has a negative Net Profit Margin of -23.60%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
GKOS
-21.43%
Health Care Equipment & Supplies Industry
- Max
- 23.34%
- Q3
- 13.06%
- Median
- 9.53%
- Q1
- 5.96%
- Min
- -3.87%
GKOS has a negative Net Profit Margin of -21.43%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
ARGX
-40.34%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
ARGX has a negative Operating Profit Margin of -40.34%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
GKOS
-22.33%
Health Care Equipment & Supplies Industry
- Max
- 29.44%
- Q3
- 17.80%
- Median
- 13.95%
- Q1
- 8.73%
- Min
- -3.56%
GKOS has a negative Operating Profit Margin of -22.33%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | ARGX | GKOS |
|---|---|---|
| Return on Equity (TTM) | 17.59% | -12.52% |
| Return on Assets (TTM) | 15.24% | -9.63% |
| Net Profit Margin (TTM) | -23.60% | -21.43% |
| Operating Profit Margin (TTM) | -40.34% | -22.33% |
| Gross Profit Margin (TTM) | 90.83% | 76.34% |
Financial Strength
Current Ratio (MRQ)
ARGX
5.60
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
ARGX’s Current Ratio of 5.60 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
GKOS
5.51
Health Care Equipment & Supplies Industry
- Max
- 4.90
- Q3
- 3.05
- Median
- 2.14
- Q1
- 1.49
- Min
- 0.86
GKOS’s Current Ratio of 5.51 is exceptionally high, placing it well outside the typical range for the Health Care Equipment & Supplies industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.
Debt-to-Equity Ratio (MRQ)
ARGX
0.01
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
ARGX’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
GKOS
0.09
Health Care Equipment & Supplies Industry
- Max
- 1.49
- Q3
- 0.71
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
Falling into the lower quartile for the Health Care Equipment & Supplies industry, GKOS’s Debt-to-Equity Ratio of 0.09 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
ARGX
-81.88
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
ARGX has a negative Interest Coverage Ratio of -81.88. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
GKOS
-28.92
Health Care Equipment & Supplies Industry
- Max
- 58.29
- Q3
- 25.56
- Median
- 9.06
- Q1
- 3.60
- Min
- -28.92
GKOS has a negative Interest Coverage Ratio of -28.92. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | ARGX | GKOS |
|---|---|---|
| Current Ratio (MRQ) | 5.60 | 5.51 |
| Quick Ratio (MRQ) | 4.92 | 4.52 |
| Debt-to-Equity Ratio (MRQ) | 0.01 | 0.09 |
| Interest Coverage Ratio (TTM) | -81.88 | -28.92 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ARGX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ARGX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
GKOS
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.05%
- Q3
- 1.76%
- Median
- 0.71%
- Q1
- 0.00%
- Min
- 0.00%
GKOS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
ARGX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ARGX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
GKOS
0.00%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 72.47%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
GKOS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ARGX | GKOS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
ARGX
30.95
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
ARGX’s P/E Ratio of 30.95 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
GKOS
--
Health Care Equipment & Supplies Industry
- Max
- 73.48
- Q3
- 51.69
- Median
- 34.31
- Q1
- 25.74
- Min
- 11.47
P/E Ratio data for GKOS is currently unavailable.
Price-to-Sales Ratio (TTM)
ARGX
29.31
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
ARGX’s P/S Ratio of 29.31 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
GKOS
12.13
Health Care Equipment & Supplies Industry
- Max
- 9.53
- Q3
- 5.26
- Median
- 3.39
- Q1
- 2.13
- Min
- 0.00
With a P/S Ratio of 12.13, GKOS trades at a valuation that eclipses even the highest in the Health Care Equipment & Supplies industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
ARGX
5.52
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
ARGX’s P/B Ratio of 5.52 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
GKOS
7.71
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 5.98
- Median
- 3.48
- Q1
- 2.43
- Min
- 0.69
GKOS’s P/B Ratio of 7.71 is in the upper tier for the Health Care Equipment & Supplies industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | ARGX | GKOS |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 30.95 | -- |
| Price-to-Sales Ratio (TTM) | 29.31 | 12.13 |
| Price-to-Book Ratio (MRQ) | 5.52 | 7.71 |
| Price-to-Free Cash Flow Ratio (TTM) | -- | 475.73 |